This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
Welcome to

A knowledge hub developed to provide information and education in oncology for healthcare professionals.

Rate this

Our activities at ESMO

Booth #248
19-23 October 2018
Munich, Germany
1 symposium
4 publications

Real-world evidence: Afatinib* in NSCLC

NSCLC in focus: information and educational resources

Investigational compounds: their MoA and clinical development

Our activities at WCLC

Access materials from our symposium and presentations at WCLC

Toronto, Canada
1 symposium
5 publications
Discover more about our activities at WCLC

Outcomes for NSCLC patients with brain metastases

Watch as Martin Schuler considers clinical data on the use of afatinib in patients with NSCLC and brain metastases

RealGiDo: a real-world study of afatinib in clinical practice

Download more information on this retrospective study of first-line afatinib dose adjustment

Treatment sequencing in EGFRM+ NSCLC

Learn more about sequencing of EGFR TKIs in this latest video with Nicolas Girard

Download Library resources

Browse freely available educational materials in our Download Library, including slide decks

inOncology Article Library

Search this library for published papers about afatinib and nintedanib**

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.